The RNA analysis market is projected to reach USD 8.7 billion by 2025 from USD 4.5 billion in 2020, at a CAGR of 13.9% during the forecast period. The growth of this market is majorly driven by the increasing demand for personalized medicine, increasing pharmaceutical and biotechnology RD expenditure and government funding for omics, and the increasing applications of RNA sequencing in the transcriptomics market.
The increasing focus on biomarker discovery and toxicogenomics, along with the increasing interest in outsourcing services, is expected to offer significant growth opportunities for the players operating in the global RNA analysis/transcriptomics market. On the other hand, the requirement of high capital investments and data management issues are expected to restrain the growth of this market to a certain extent.
According to our findings, the RNA analysis/transcriptomics market is expected to grow at an approximate CAGR of 15–17% for the next two years. The factors listed below would play a key role in shaping the growth of the global market;
According to the Personalized Medicine Coalition report (2017), the number of personalized drugs, treatments, and diagnostic products has increased since 2006, and this trend is expected to continue in the coming years.
With the widespread implementation of novel applications, the use of transcriptomics research extends all the way from the discovery of novel drugs, vaccines, and diagnostic targets, toxicology, and identification of surrogate markers of activity in clinical research to the ability to provide information on the mechanisms of drug action. This requires the use of different types of platforms and instruments as well as laboratory documentation systems, contributing to the high cost of analytics.
Download PDF Brochure With Latest Edition @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240344576
Biomarker identification, along with its clinical applications, has simplified drug discovery and development procedures in terms of evaluating the toxicity and efficacy of drugs. Besides, biomarkers for diseases like cancer, CVD, and neurological diseases are playing an integral role in enabling a better understanding of the disease pathway and progression.
The microarray technology used in transcriptomic analysis offers the promise of widespread study of diseases at the genomic level. It also aids in developing novel clinical biomarkers, identifying novel molecular abnormalities, and investigating drug efficacy.
Moreover, RNA sequencing data from transcriptomics studies have low genome coverage and high amplification bias, which makes data analysis extremely challenging, especially without effective bioinformatics tools. Many existing tools developed for bulk cell sequencing have not been effective in the analysis of transcriptomics data. This poses several challenges in terms of difficulties in calling copy number variations, identifying mutated genes in tumor samples, reconstructing cell lineages, recovering low abundant transcripts, and improving the accuracy of quantitative analysis of transcripts.
Currently, there is a greater need from researchers for technical standards and bioinformatics software and databases to evaluate genome coverage and amplification bias, so that the results from different technologies can be compared with each other.
The increasing demand for high-quality reagents and the repeated use of media and reagents in transcriptome studies. Additionally, the growing RD activities in the pharmaceutical industry, growing government investments in the field of life science research, and the increasing research being undertaken with integrated omics studies are contributing to the market for consumables.
To get more details on this report : https://www.marketsandmarkets.com/requestsampleNew.asp?id=240344576
The sequencing technologies segment is expected to witness the highest growth during the forecast period. RNA sequencing allows direct access to sequences of mRNA and is an equitable technology, which makes it more suitable for target identification and drug discovery applications. RNA sequencing also helps overcome several issues associated with microarrays, such as bias and variation due to hybridization and labeling efficiencies. Technological advancements in this segment are further set to drive market growth.
The drug discovery segment accounted for the largest share of the market in 2019. This is attributed to the use of transcriptomics in drug discovery for target identification and validation, identification of efficacy and toxicity biomarkers from biological fluids, and investigation of drug action and toxicity mechanisms. The growing need to study a large number of genes to gain a better understanding of gene-to-drug interactions is further expected to drive the use of transcriptomic technologies in drug discovery applications.
The contract research organizations (CROs) segment is expected to
witness the highest growth during the forecast period. CROs provide affordable outlets for companies and academia to pursue new medicines and offer a cost-effective solution to developing drugs. They also support foundations, research institutions, and universities, in addition to government organizations, such as the NIH and EMA. These factors are driving the growth of this segment.
The large share of this market segment can be attributed to the increasing development of structure-based drug designs, growing academic and government investments in genomics and proteomics research, high life science research funding, high biopharmaceutical RD expenditure, and the greater adoption of advanced technologies in North America. The presence of a large number of global players in this region is another key factor contributing to the large share of this market segment.
Key Market Players
The prominent players in this market are Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US).
#RNA Analysis/ Transcriptomics Market #RNA Analysis/ Transcriptomics #RNA Analysis
This report studies the global market size of Colonoscopy in key regions like North America, Europe,Asia Pacific, Central & South America and Middle East & Africa, focuseson the consumption of Colonoscopy inthese regions.
This report also studies the global market status, competitionlandscape, market share, growth rate, future trends, market drivers,opportunities and challenges, sales channels, distributors and Porter’s FiveForces Analysis.
Market size split by Region
Rest of Central & South America
Do Inquiry BeforeAccessing Global Colonoscopy Market Report at https://www.orbisresearch.com/contacts/enquiry-before-buying/2374234 .
Focuses on the key global Colonoscopy manufacturers, to define, describe and analyzethe sales volume, value, market share, market competition landscape, SWOTanalysis and development plans in next few years.
